source · text/markdown
source_b6b91636d27e45d2
sha256 e57947f28c0f4630b60064ce0d95102e81f1e94fd16e3f1c56bb3a21d365ffe6
by researka:v2 · 2026-07-02 16:23:23.963428+04:00
# Hypothesis-Generating Brief: Pcsk9 Inhibitors Effects — full paper ## Abstract Evidence-honesty note: 33/36 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Pcsk9 Inhibitors Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. PCSK9 inhibitors, monoclonal antibodies and small-interfering RNA agents targeting proprotein convertase subtilisin/kexin type 9, have become a focal adjunctive lipid-lowering strategy for patients with hypercholesterolemia in patients with atherosclerotic cardiovascular disease, where residual LDL-C-driven risk persists despite maximally tolerated statin therapy. Although their LDL-C lowering capacity is well documented, the clinical community still needs clarity on whether reductions in this surrogate biomarker reliably translate into reductions in hard cardiovascular endpoints such as myocardial infarction, stroke, and cardiovascular mortality — a question that invites methodological caution about surrogate endpoints (Ioannidis 2005) — and on whether safety signals in non-cardiac organ systems emerge with broader use. We conducted an AI-assisted structured evidence synthesis with a complete audit trail, drawing on 36 curated references including randomized controlled trials, systematic reviews, network meta-analyses, and observational cohorts, and stratified findings by outcome class (cardiometabolic, safety, safety-comorbidity, mortality/survival, muscle function, skeletal/bone, longevity, and contextual other) and by directness of evidence. Cao 2025 corroborated a positive cardiometabolic signal in post-PCI populations, Imran 2023 documented favorable lipid and event profiles with evolocumab and alirocumab, and Raone 2025 found that both evolocumab (140 mg every 2 weeks or 420 mg monthly) and alirocumab 150 mg every 2 weeks significantly reduced MACE versus placebo in ASCVD. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence. ## Methods ### Review type and protocol This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-pcsk9_inhibitors_effects-v06-DAILY-2026-07-02T12-15-39Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-02. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `PCSK9 inhibitors effects aging` - `PCSK9 inhibitors effects older adults` - `PCSK9 inhibitors effects randomized controlled trial` - `PCSK9 inhibitors aging` - `PCSK9 inhibitors older adults` - `PCSK9 inhibitors randomized controlled trial` ### Eligibility criteria - Sources whose primary content addresses pcsk9 inhibitors effects. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 162 records in the receipt-candidate union, 42 were classified as source candidates and 36 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | source candidate union | 162 | | Classified source candidates | 42 | | No extractable claims | 15 | | None-only claim binding | 6 | | Mixed partial-or-none claim-binding candidates | 66 | | Partial-only claim-binding candidates | 20 | | Strict high-confidence sources | 13 | | Admitted final sources | 36 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity, mortality and survival, muscle function, safety, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Evidence Landscape ### Findings Map Findings Map completeness note: all 36 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords. | Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding | | --- | --- | --- | --- | --- | --- | --- | | Cardiometabolic | Ariyanti 2026: Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis. | direction=negative | directness=review | B1 | outcome=Cardiometabolic; direction=negative | finding=3 extracted claim(s); source-level direction is the coded finding | | Cardiometabolic | Cao 2025: Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis | direction=positive | directness=review | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | | Cardiometabolic | Du 2019: Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=9 extracted claim(s); source-level direction is the coded finding | | Cardiometabolic | Gong 2025: Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China | direction=null | directness=direct | A1 | outcome=Cardiometabolic; direction=null | finding=13 extracted claim(s); source-level direction is the coded finding | | Cardiometabolic | Hollstein 2021: PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.0001; source-level statistic reported | | Cardiometabolic | Imran 2023: Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis | direction=positive | directness=review | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.01; source-level statistic reported | | Cardiometabolic | Khan 2018: A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=9 extracted claim(s); source-level direction is the coded finding | | Cardiometabolic | Raone 2025: Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=62 extracted claim(s); source-level direction is the coded finding | | Cardiometabolic | Ray 2025: The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=8 extracted claim(s); source-level direction is the coded finding | | Cardiometabolic | Rehues 2023: PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | | Cardiometabolic | Scicali 2021: Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=representative statistic P < 0.05; source-level statistic reported | | Cardiometabolic | Turgeon 2018: Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding | | Cardiometabolic | Wang 2022a: PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative statistic P = 0.029; source-level statistic reported | | Cardiometabolic | Wang 2022b: Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=representative non-significant statistic P = 0.38; not treated as positive or negative directional support unless source direction is coded | | Contextual Adjacent Evidence | Akhtar 2025: PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | | Contextual Adjacent Evidence | Barbati 2024: Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=29 extracted claim(s); source-level direction is the coded finding | | Contextual Adjacent Evidence | Bosco 2025: Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | | Contextual Adjacent Evidence | Chen 2026: PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=40 extracted claim(s); source-level direction is the coded finding | | Contextual Adjacent Evidence | Hosseini 2024: Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis | direction=unclear | directness=review | B1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=108 extracted claim(s); source-level direction is the coded finding | | Contextual Adjacent Evidence | Jing 2025: Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | | Contextual Adjacent Evidence | Kuhl 2019: Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | | Contextual Adjacent Evidence | Seijas-Amigo 2023: Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.216; not treated as positive or negative directional support unless source direction is coded | | Contextual Adjacent Evidence | Yu 2026: Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | | Longevity | Hu 2025: Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis. | direction=unclear | directness=review | B1 | outcome=Longevity; direction=unclear | finding=2 extracted claim(s); source-level direction is the coded finding | | Mortality and Survival | Zhang 2025: Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials | direction=null | directness=review | B2 | outcome=Mortality and Survival; direction=null | finding=representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded | | Muscle Function | Li 2024: PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis | direction=null | directness=review | B2 | outcome=Muscle Function; direction=null | finding=representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded | | Safety | Choi 2023: An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors | direction=unclear | directness=review | B2 | outcome=Safety; direction=unclear | finding=43 extracted claim(s); source-level direction is the coded finding | | Safety | Karatasakis 2017: Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials | direction=mixed | directness=direct | A1 | outcome=Safety; direction=mixed | finding=representative statistic P < 0.001; source-level statistic reported | | Safety | Schmidt 2017: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. | direction=null | directness=review | B1 | outcome=Safety; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding | | Safety and Comorbidity | Jiang 2025: Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded | | Safety and Comorbidity | Liu 2024: The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=71 extracted claim(s); source-level direction is the coded finding | | Safety and Comorbidity | Masson 2026: Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=40 extracted claim(s); source-level direction is the coded finding | | Safety and Comorbidity | Song 2024: Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis | direction=mixed | directness=review | B1 | outcome=Safety and Comorbidity; direction=mixed | finding=representative non-significant statistic P = 0.08; not treated as positive or negative directional support unless source direction is coded | | Safety and Comorbidity | Theodorou 2025: Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance | direction=null | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=null | finding=7 extracted claim(s); source-level direction is the coded finding | | Safety and Comorbidity | Xiao 2024: Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=representative non-significant statistic P = 0.60; not treated as positive or negative directional support unless source direction is coded | | Skeletal, Fracture, and Bone | Chen 2024: PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis | direction=mixed | directness=review | B2 | outcome=Skeletal, Fracture, and Bone; direction=mixed | finding=representative statistic P < 0.05; source-level statistic reported | ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Pcsk9 Inhibitors Effects / Cardiometabolic | n=14; claims=634 | significant source statistic in 6/14 sources; receipt-level direction coded unclear | 1 direct; 3 indirect; 10 review | limited corpus depth in this outcome class | | Pcsk9 Inhibitors Effects / Contextual Adjacent Evidence | n=9; claims=394 | significant source statistic in 6/9 sources; receipt-level direction coded unclear | 1 direct; 7 indirect; 1 review | limited corpus depth in this outcome class | | Pcsk9 Inhibitors Effects / Safety and Comorbidity | n=6; claims=276 | significant source statistic in 1/6 sources; receipt-level direction coded null | 1 indirect; 5 review | limited corpus depth in this outcome class | | Pcsk9 Inhibitors Effects / Safety | n=3; claims=139 | significant source statistic in 1/3 sources; receipt-level direction coded unclear | 1 direct; 2 review | limited corpus depth in this outcome class | | Pcsk9 Inhibitors Effects / Longevity | n=1; claims=2 | unclear signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | | Pcsk9 Inhibitors Effects / Mortality and Survival | n=1; claims=31 | reported statistic in 1/1 sources; receipt-level direction coded null | 1 review | single-source slice; hypothesis-generating | | Pcsk9 Inhibitors Effects / Muscle Function | n=1; claims=40 | reported statistic in 1/1 sources; receipt-level direction coded null | 1 review | single-source slice; hypothesis-generating | | Pcsk9 Inhibitors Effects / Skeletal, Fracture, and Bone | n=1; claims=32 | mixed signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | **Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect. - Skeletal and muscle context: 2 sources; significant source statistic in 1/2 sources; receipt-level direction coded null. - Transplant and fibrosis context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear. ### Cardiometabolic Outcomes Cardiometabolic remains a separate Results slice for Pcsk9 Inhibitors Effects (n=14; claims=634; significant source statistic in 6/14 sources; receipt-level direction coded unclear; 1 direct; 3 indirect; 10 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Hollstein 2021 (PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular; representative statistic P < 0.0001; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2). - Imran 2023 (Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk; representative statistic p<0.01; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=review; tier=B2). - Scicali 2021 (Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial; representative statistic p < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=null; directness=indirect; tier=B2). - Rehues 2023 (PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile; representative statistic p < 0.001; source-level statistic reported; outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2). Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction. ### Contextual Adjacent Evidence Outcomes Contextual Adjacent Evidence remains a separate Results slice for Pcsk9 Inhibitors Effects (n=9; claims=394; significant source statistic in 6/9 sources; receipt-level direction coded unclear; 1 direct; 7 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Jing 2025 (Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2). - Bosco 2025 (Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in; representative statistic p < 0.001; source-level statistic reported; outcome=Biomarker/Adjacent Evidence; direction=unclear; directness=indirect; tier=B2). - Kuhl 2019 (Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation; representative statistic p<0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2). - Seijas-Amigo 2023 (Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real; representative non-significant statistic p = 0.216; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2). ### Longevity Outcomes Longevity remains a separate Results slice for Pcsk9 Inhibitors Effects (n=1; claims=2; unclear signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Hu 2025 (Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a; 2 extracted claim(s); receipt-level direction is the coded finding; outcome=Longevity; direction=unclear; directness=review; tier=B1). ### Mortality and Survival Outcomes Mortality and Survival remains a separate Results slice for Pcsk9 Inhibitors Effects (n=1; claims=31; reported statistic in 1/1 sources; receipt-level direction coded null; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Zhang 2025 (Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A; representative non-significant statistic P = 0.40; not treated as positive or negative directional support unless source direction is coded; outcome=Mortality and Survival; direction=null; directness=review; tier=B2). ### Safety and Comorbidity Outcomes Safety and Comorbidity remains a separate Results slice for Pcsk9 Inhibitors Effects (n=6; claims=276; significant source statistic in 1/6 sources; receipt-level direction coded null; 1 indirect; 5 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Song 2024 (Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary; representative non-significant statistic P = .08; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=mixed; directness=review; tier=B1). - Xiao 2024 (Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial; representative non-significant statistic p = 0.60; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2). - Jiang 2025 (Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein; representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2). - Liu 2024 (The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in; 71 extracted claim(s); receipt-level direction is the coded finding; outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2). ### Safety Outcomes Safety remains a separate Results slice for Pcsk9 Inhibitors Effects (n=3; claims=139; significant source statistic in 1/3 sources; receipt-level direction coded unclear; 1 direct; 2 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Karatasakis 2017 (Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized; representative statistic P <0.001; source-level statistic reported; outcome=Safety; direction=mixed; directness=direct; tier=A1). - Choi 2023 (An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors; 43 extracted claim(s); receipt-level direction is the coded finding; outcome=Safety; direction=unclear; directness=review; tier=B2). - Schmidt 2017 (PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.; 2 extracted claim(s); receipt-level direction is the coded finding; outcome=Safety; direction=null; directness=review; tier=B1). ### Muscle Function Outcomes Muscle Function remains a separate Results slice for Pcsk9 Inhibitors Effects (n=1; claims=40; reported statistic in 1/1 sources; receipt-level direction coded null; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Li 2024 (PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a; representative non-significant statistic P = 0.22; not treated as positive or negative directional support unless source direction is coded; outcome=Muscle Function; direction=null; directness=review; tier=B2). ### Skeletal, Fracture, and Bone Outcomes Skeletal, Fracture, and Bone remains a separate Results slice for Pcsk9 Inhibitors Effects (n=1; claims=32; mixed signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Chen 2024 (PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis; representative statistic P < 0.05; source-level statistic reported; outcome=Skeletal, Fracture, and Bone; direction=mixed; directness=review; tier=B2). ## What This Synthesis Adds This synthesis maps 36 included sources on Pcsk9 Inhibitors Effects across 8 outcome classes and 106 cross-study disagreements. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit. Across 36 curated reference papers, the evidence base for Pcsk9 shows a context-dependent profile. Positive signals appear in: cardiometabolic, contextual other. Null findings dominate: safety comorbidity, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Pcsk9 broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest unresolved contrast is the null vs positive between Imran 2023 and Ray 2025 on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. Prior reviews in the corpus (Hosseini 2024, Raone 2025, Song 2024, Khan 2018, Du 2019) emphasize convergent signals on Pcsk9 Inhibitors Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | muscle function | 0 | 1 | null | direct interventional hard-endpoint gap | | longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap | | cardiometabolic | 1 | 13 | null, positive, unclear | conflict-resolution gap | | safety | 1 | 2 | mixed, null, unclear | replication gap | | mortality and survival | 0 | 1 | null | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 6 | mixed, null | direct interventional hard-endpoint gap | | skeletal, fracture, and bone | 0 | 1 | mixed | direct interventional hard-endpoint gap | | contextual adjacent evidence | 1 | 8 | null, positive, unclear | replication gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P2 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P3 | cardiometabolic: conflict-resolution gap | 1 direct and 13 indirect sources; direction profile: null, positive, unclear | | P4 | safety: replication gap | 1 direct and 2 indirect sources; direction profile: mixed, null, unclear | | P5 | mortality and survival: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | ### Next-Study Design Recommendation The next high-yield study for Pcsk9 Inhibitors Effects should target the **muscle function** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Karatasakis 2017; tier=A1; directness=direct; endpoint=safety; direction=mixed; representative statistic=P < 0.001. - Chen 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. - Gong 2025; tier=A1; directness=direct; endpoint=cardiometabolic; direction=null. - Hosseini 2024; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear. - Raone 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Song 2024; tier=B1; directness=review; endpoint=safety comorbidity; direction=mixed; representative statistic=P < 0.00001. - Du 2019; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Khan 2018; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Ariyanti 2026; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear. - Hu 2025; tier=B1; directness=review; endpoint=longevity; direction=unclear. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Karatasakis 2017: outcome=safety; directness=direct; tier=A1; direction=mixed; claims=94. - Chen 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=40. - Gong 2025: outcome=cardiometabolic; directness=direct; tier=A1; direction=null; claims=13. - Hosseini 2024: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=108. - Raone 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=62. - Song 2024: outcome=safety comorbidity; directness=review; tier=B1; direction=mixed; claims=59. - Du 2019: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=9. - Khan 2018: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=9. - Ariyanti 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=3. - Hu 2025: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=2. - Schmidt 2017: outcome=safety; directness=review; tier=B1; direction=null; claims=2. - Turgeon 2018: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=2. - Hollstein 2021: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=105. - Imran 2023: outcome=cardiometabolic; directness=review; tier=B2; direction=positive; claims=95. - Scicali 2021: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=92. - Rehues 2023: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=87. - Cao 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=positive; claims=82. - Liu 2024: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=71. - Jing 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=70. - Xiao 2024: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=59. - Choi 2023: outcome=safety; directness=review; tier=B2; direction=unclear; claims=43. - Wang 2022a: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=42. - Jiang 2025: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=40. - Li 2024: outcome=muscle function; directness=review; tier=B2; direction=null; claims=40. - Masson 2026: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=40. - Bosco 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=39. - Kuhl 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=39. - Chen 2024: outcome=skeletal fracture bone; directness=review; tier=B2; direction=mixed; claims=32. - Zhang 2025: outcome=mortality survival; directness=review; tier=B2; direction=null; claims=31. - Barbati 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=29. - Seijas-Amigo 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=27. - Wang 2022b: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=25. - Akhtar 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=22. - Yu 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=20. - Ray 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=8. - Theodorou 2025: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=7. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Severity 4 null vs positive: Imran 2023 vs Ray 2025; Imran 2023 (positive on cardiometabolic) vs Ray 2025 (null on cardiometabolic) — partial conflict - Severity 4 null vs positive: Imran 2023 vs Scicali 2021; Imran 2023 (positive on cardiometabolic) vs Scicali 2021 (null on cardiometabolic) — partial conflict - Severity 4 null vs positive: Imran 2023 vs Wang 2022b; Imran 2023 (positive on cardiometabolic) vs Wang 2022b (null on cardiometabolic) — partial conflict - Severity 4 null vs positive: Ray 2025 vs Cao 2025; Cao 2025 (positive on cardiometabolic) vs Ray 2025 (null on cardiometabolic) — partial conflict - Severity 4 null vs positive: Cao 2025 vs Scicali 2021; Cao 2025 (positive on cardiometabolic) vs Scicali 2021 (null on cardiometabolic) — partial conflict - Severity 4 null vs positive: Cao 2025 vs Wang 2022b; Cao 2025 (positive on cardiometabolic) vs Wang 2022b (null on cardiometabolic) — partial conflict - Severity 3 indirectness gap: Seijas-Amigo 2023 vs Chen 2026; Chen 2026 (direct, A1) vs Seijas-Amigo 2023 (indirect) on contextual other — direct vs indirect must be kept separate - Severity 3 indirectness gap: Imran 2023 vs Gong 2025; Gong 2025 (direct, A1) vs Imran 2023 (review) on cardiometabolic — direct vs indirect must be kept separate ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The principal limitation is evidence-role imbalance. The retained corpus contains 3 direct clinical sources, 33 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, which means causal interpretation depends on how much weight is assigned to each evidence tier. A second limitation is endpoint heterogeneity. Study-level signals span the cardiometabolic and contextual adjacent evidence outcome classes, the safety and comorbidity, cardiometabolic, muscle function outcome classes, no dominant outcome class, and the safety, safety and comorbidity, skeletal, fracture, and bone outcome classes; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design. A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review. This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two. The final interpretation is therefore intentionally resistant to overstatement. It can support publication-grade synthesis when the evidence profile is transparent, but it does not convert plausible translation into certainty without matching direct evidence. Readers can weigh each section against the provenance trail published with the run. Every quantitative statement links back to an extraction source, and every source names its source document, so disagreement between summary and source is detectable rather than silent. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. ## Conclusion For pcsk9 inhibitors effects, the final interpretation is deliberately tiered: the retained direct, adjacent, and context evidence profile defines a bounded evidence rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general efficacy endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent/context evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support pcsk9 inhibitors effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone longevity intervention with proven hard clinical-outcome effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## References - **Hosseini 2024.** _Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis._ BMC Cardiovascular Disorders, 2024. DOI: 10.1186/s12872-024-04057-w PMID: 39080549. - **Hollstein 2021.** _PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks._ American Journal of Cardiovascular Drugs, 2021. DOI: 10.1007/s40256-020-00411-3 PMID: 32514867. - **Imran 2023.** _Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis._ PLOS ONE, 2023. DOI: 10.1371/journal.pone.0295359 PMID: 38055686. - **Karatasakis 2017.** _Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017. DOI: 10.1161/JAHA.117.006910 PMID: 29223954. - **Scicali 2021.** _Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting._ Acta Diabetologica, 2021. DOI: 10.1007/s00592-021-01703-z PMID: 33745063. - **Rehues 2023.** _PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk._ International Journal of Molecular Sciences, 2023. DOI: 10.3390/ijms24032319 PMID: 36768645. - **Cao 2025.** _Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis._ Frontiers in Cardiovascular Medicine, 2025. DOI: 10.3389/fcvm.2025.1612095 PMID: 41235335. - **Liu 2024.** _The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis._ Frontiers in Cardiovascular Medicine, 2024. DOI: 10.3389/fcvm.2024.1454918 PMID: 39386388. - **Jing 2025.** _Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-26495-y PMID: 41309899. - **Raone 2025.** _Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis._ American Journal of Cardiovascular Drugs, 2025. DOI: 10.1007/s40256-025-00778-1 PMID: 41420785. - **Song 2024.** _Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis._ Medicine, 2024. DOI: 10.1097/MD.0000000000038360 PMID: 39259104. - **Xiao 2024.** _Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis._ Medicina, 2024. DOI: 10.3390/medicina60101646 PMID: 39459433. - **Choi 2023.** _An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors._ Cardiovascular Therapeutics, 2023. DOI: 10.1155/2023/7362551 PMID: 36704607. - **Wang 2022a.** _PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis._ Cardiovascular Diabetology, 2022. DOI: 10.1186/s12933-022-01542-4 PMID: 35706032. - **Li 2024.** _PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis._ Frontiers in Cardiovascular Medicine, 2024. DOI: 10.3389/fcvm.2024.1375040 PMID: 39040999. - **Jiang 2025.** _Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis._ Frontiers in Cardiovascular Medicine, 2025. DOI: 10.3389/fcvm.2024.1415668 PMID: 39975967. - **Masson 2026.** _Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis._ Advances in Therapy, 2026. DOI: 10.1007/s12325-025-03418-x PMID: 41288928. - **Chen 2026.** _PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial._ BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-112947 PMID: 41857839. - **Bosco 2025.** _Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects._ Journal of Translational Medicine, 2025. DOI: 10.1186/s12967-025-07432-z PMID: 41331636. - **Kuhl 2019.** _Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation._ PLoS ONE, 2019. DOI: 10.1371/journal.pone.0210373 PMID: 30650126. - **Chen 2024.** _PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis._ BMC Musculoskeletal Disorders, 2024. DOI: 10.1186/s12891-024-07674-w PMID: 39010016. - **Zhang 2025.** _Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials._ PLOS One, 2025. DOI: 10.1371/journal.pone.0329676 PMID: 40779566. - **Barbati 2024.** _Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records._ PLOS ONE, 2024. DOI: 10.1371/journal.pone.0309470 PMID: 39173034. - **Seijas-Amigo 2023.** _Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study._ American Journal of Cardiovascular Drugs, 2023. DOI: 10.1007/s40256-023-00604-6 PMID: 37612529. - **Wang 2022b.** _Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat._ Frontiers in Cardiovascular Medicine, 2022. DOI: 10.3389/fcvm.2022.1016802 PMID: 36531722. - **Akhtar 2025.** _PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-22916-0 PMID: 41087577. - **Yu 2026.** _Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment._ Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2026. DOI: 10.1161/JAHA.125.047923 PMID: 42017316. - **Gong 2025.** _Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China._ Trials, 2025. DOI: 10.1186/s13063-024-08709-2 PMID: 39762992. - **Khan 2018.** _A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes._ Eur J Prev Cardiol, 2018. DOI: 10.1177/2047487318766612 PMID: 29569492. - **Du 2019.** _Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis._ Heart, 2019. DOI: 10.1136/heartjnl-2019-314763 PMID: 30842207. - **Ray 2025.** _The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis._ Current Cardiology Reviews, 2025. DOI: 10.2174/011573403X345749250122092324 PMID: 39950470. - **Theodorou 2025.** _Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance._ European Journal of Neurology, 2025. DOI: 10.1111/ene.70175 PMID: 40522062. - **Ariyanti 2026.** _Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis._ Curr Med Res Opin, 2026. DOI: 10.1080/03007995.2026.2662127 PMID: 42057683. - **Schmidt 2017.** _PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease._ Cochrane Database Syst Rev, 2017. DOI: 10.1002/14651858.cd011748.pub2 PMID: 28453187. - **Turgeon 2018.** _Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial._ Can J Cardiol, 2018. DOI: 10.1016/j.cjca.2018.04.002 PMID: 30527147. - **Hu 2025.** _Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis._ Coron Artery Dis, 2025. DOI: 10.1097/mca.0000000000001464 PMID: 39620869. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.
metadata
{
"article_type": "evidence_map",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "03db8fe9-e32f-450e-a315-31c6aa738dcc",
"title": "Hypothesis-Generating Brief: Pcsk9 Inhibitors Effects \u2014 full paper"
}